1334166-66-3

Basic information

• Product Name: 3-[1-(2-chlorobenzyl)-1H-pyrazol-4-yl]-2-methyl-8-morpholin-4-ylimidazo[1,2-a]pyrazine
• CAS NO: 1334166-66-3
• Molecular Weight: 408.89
• Mol File: 1334166-66-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-[1-(2-chlorobenzyl)-1H-pyrazol-4-yl]-2-methyl-8-morpholin-4-ylimidazo[1,2-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[1-(2-chlorobenzyl)-1H-pyrazol-4-yl]-2-methyl-8-morpholin-4-ylimidazo[1,2-a]pyrazine(1334166-66-3)
• EPA Substance Registry System: 3-[1-(2-chlorobenzyl)-1H-pyrazol-4-yl]-2-methyl-8-morpholin-4-ylimidazo[1,2-a]pyrazine(1334166-66-3)

Safety Data

• Hazardous Substances Data: 1334166-66-3(Hazardous Substances Data)

Upstream product

• 957265-68-8 1-(2-chlorobenzyl)-4-iodo-1H-pyrazole 
• 611-19-8 1-chloro-2-(chloromethyl)benzene 
• 85333-43-3 8-chloro-2-methyl-imidazo[1,2-a]pyrazine 
• 1334167-41-7 3-bromo-2-methyl-8-morpholin-4-ylimidazo[1,2-a]pyrazine 
• 1430750-66-5 1-[(2-chlorophenyl)methyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole 
• 1124321-36-3 3-bromo-8-chloro-2-methyl-imidazo[1,2-a]pyrazine 

Relevant articles and documents

Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia

We report the discovery of a series of imidazo[1,2-a]pyrazine derivatives as novel inhibitors of phosphodiesterase 10A (PDE10A). In a high-throughput screening campaign we identified the imidazopyrazine derivative 1, a PDE10A inhibitor with limited select

IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.